Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in FSGS and MCD
NCT04009668Phase 2Completed
- Sponsor
- University of Michigan
- Start
- Oct 2019
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of adalimumab in focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), sponsored by University of Michigan. Started Oct 2019; status: completed.
02
Drugs
03
Conditions
focal segmental glomerulosclerosis (FSGS)minimal change disease (MCD)
Beyond the preview
Go deeper on NCT04009668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04009668.